Recently passed legislation will ensure pharmaceutical companies report shortages of medicines. This is only about notifications. It won’t prevent medicine shortages themselves.
Academic rigour, journalistic flair
Articles on EpiPen
Displaying all articles
The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
Why drug maker Mylan’s decision to introduce a half-price version of its EpiPen could be more than a publicity stunt.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Job Board
-
Senior Lecturer - Earth System Science
-
Associate Director, Operational Planning
-
Sydney Horizon Educators (Identified)
-
Deputy Social Media Producer
-
Associate Professor, Occupational Therapy
Top contributors
-
Lecturer, Pharmacy Practice, University of Sydney
-
Associate Professor of Law, Washington University in St. Louis
-
Professor of Law, University of Denver
-
Associate Professor, University of East Anglia
-
Associate Professor, University of Sydney
-
Associate professor, Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney
